Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Matinas BioPharma Holdings Inc MTNB

Healthcare Biotechnology
Matinas BioPharma Holdings, Inc. is a biopharmaceutical company. The Company is focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology (LNC Platform). Its lead product candidate is MAT2203 (oral amphotericin B), a highly potent antifungal drug which, by virtue of LNC delivery, has been made oral, safe, and well-tolerated for prolonged... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NYSEAM:MTNB)

Matinas BioPharma to Webcast Conference Call to Discuss First Quarter 2024 Financial Results and Provide a Business Update on May 9, 2024

GlobeNewswire 4 days ago

In Vivo Efficacy of Matinas BioPharma's Oral MAT2203 in Pulmonary Mucormycosis Published in Journal of Antimicrobial Agents and Chemotherapy

GlobeNewswire 6 days ago

Matinas BioPharma Prices $10 Million Registered Direct Offering

GlobeNewswire April 3, 2024

Matinas BioPharma Reports 2023 Financial Results and Provides a Business Update

GlobeNewswire March 27, 2024

Matinas BioPharma Announces Positive in vivo Safety Data with its Oral LNC-Docetaxel Formulation

GlobeNewswire March 25, 2024

Three Patients with Invasive Fusarium Infection in Matinas BioPharma's Oral MAT2203 Compassionate/Expanded Use Access Program Achieve Complete Clinical Response

GlobeNewswire March 22, 2024

Matinas BioPharma Regains Compliance with NYSE American Continued Listing Standards

GlobeNewswire March 22, 2024

Matinas BioPharma Provides Positive Outcomes Update on the MAT2203 Compassionate/Expanded Use Access Program, Including Multiple Patients with Complete Clinical Resolution

GlobeNewswire February 26, 2024

Matinas BioPharma Successfully Reaches Agreement with FDA for a Single Phase 3 Registration Trial to Support an NDA for MAT2203 for the Treatment of Invasive Aspergillosis

GlobeNewswire February 20, 2024
View More News ››

Opinion & Analysis (NYSEAM:MTNB)

Clinical Trial Starts for Biopharma's Antifungal in Cryptococcal Meningitis

Streetwise Reports October 23, 2019

Now Cashed Up, Biopharma to Advance Cholesterol-Lowering Therapy

Streetwise Reports March 25, 2019
View More Opinion ››

Bullboard Posts (NYSEAM:MTNB)

Matinas BioPharma Provides Positive Outcomes Update on the M

BREAKING NEWS: $MTNB Matinas BioPharma Provides Positive Outcomes Update on the MAT2203 Compassionate/Expanded Use Access Program...
whytestocks - February 26, 2024

RE:it's time to go up again

Matinas BioPharma (NYSEMKT:MTNB) is up 4% postmarket following a start at Buy by SunTrust Robinson Humphrey. The firm's set its...
panda55 - January 24, 2020

it's time to go up again

for this one,so glta.
coolfooldumbguy - January 21, 2020

added more of this one

it has been almost a year and this one was up big time last spring,should have sold it then,but it is going up again ,so doubling down on...
coolfooldumbguy - September 25, 2019

it's a buy today for me

looks like a turnaround stock & the chart has formed a perfect head & shoulders,so glta.
coolfooldumbguy - October 18, 2018
View more Bullboard ››

BioVaxys Technology Corp.

BioVaxys Technology Corp.

BioVaxys Technology Corp. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on improving ...
View More »